A Single Common Assay for Robust and Rapid Fragile X Mental Retardation Syndrome Screening From Dried Blood Spots by Winarni, Tri Indah
fgene-09-00582 November 24, 2018 Time: 16:19 # 1
ORIGINAL RESEARCH
published: 27 November 2018
doi: 10.3389/fgene.2018.00582
Edited by:
Babajan Banganapalli,
King Abdulaziz University,
Saudi Arabia
Reviewed by:
Bruna De Felice,
Università degli Studi della Campania
“Luigi Vanvitelli”, Italy
Nelson L. S. Tang,
The Chinese University of Hong Kong,
China
*Correspondence:
Samuel S. Chong
paecs@nus.edu.sg;
samuel_chong@nuhs.edu.sg
Specialty section:
This article was submitted to
Genetic Disorders,
a section of the journal
Frontiers in Genetics
Received: 11 May 2018
Accepted: 08 November 2018
Published: 27 November 2018
Citation:
Tan VJ, Lian M, Faradz SMH,
Winarni TI and Chong SS (2018) A
Single Common Assay for Robust
and Rapid Fragile X Mental
Retardation Syndrome Screening
From Dried Blood Spots.
Front. Genet. 9:582.
doi: 10.3389/fgene.2018.00582
A Single Common Assay for Robust
and Rapid Fragile X Mental
Retardation Syndrome Screening
From Dried Blood Spots
Vivienne J. Tan1, Mulias Lian2, Sultana M.H. Faradz3, Tri I. Winarni and
Samuel S. Chong1,2,4*
1 Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore,
2 Khoo Teck Puat – National University Children’s Medical Institute, National University Health System, Singapore, Singapore,
3 Division of Human Genetics, Center for Biomedical Research, Faculty of Medicine, Diponegoro University, Semarang,
Indonesia, 4 Department of Laboratory Medicine, National University Hospital, National University Health System, Singapore,
Singapore
Background: FMR1 CGG trinucleotide repeat hyper-expansions are observed in 99%
of individuals with fragile X mental retardation syndrome (FXS). We evaluated the
reliability of a rapid single-step gender-neutral molecular screen for FXS when performed
on DNA isolated from dried blood spots.
Methods: DNA was extracted from dried blood spots of 151 individuals with intellectual
disability or autism spectrum disorder, whose FMR1 repeat genotypes are known. Dried
blood spots were blinded prior to DNA extraction and analysis by triplet primed PCR
(TP-PCR) and melt curve analysis (MCA). All expansion-positive and representative
expansion-negative samples were also genotyped by fluorescent TP-PCR and capillary
electrophoresis (CE) to confirm repeat expansion status.
Results: Three males and 12 females were classified as expanded by TP-PCR MCA,
and were subsequently sized by fluorescent TP-PCR CE. Two males and four females
carried premutations, while one male and eight females carried full mutations. All 19
non-expanded samples that were sized were confirmed as carrying only normal alleles.
Replicate analysis of representative expansion-positive samples yielded reproducible
melt peak profiles. TP-PCR MCA classifications were completely concordant with FMR1
CGG repeat genotypes.
Conclusion: TP-PCR MCA of dried blood spot DNA accurately and reliably identifies
presence/absence of FMR1 CGG repeat expansions in both genders simultaneously.
This strategy may be suitable for rapid high-throughput first-tier screening for fragile X
syndrome.
Keywords: fragile X syndrome, FMR1, trinucleotide repeat, dried blood spot, triplet-primed PCR (TP-PCR), melt
curve analysis (MCA)
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INTRODUCTION
Fragile X syndrome (FXS; OMIM 309550) is a leading
genetic cause of intellectual disability and autism spectrum
disorders. Clinical manifestations include neuro-developmental
delay, anxiety, mild to severe intellectual impairment, and
macroorchidism in prepubertal males (McLennan et al., 2011).
FXS generally affects one in 4000 males and one in 2000–8000
females (Monaghan et al., 2013).
Ninety-nine percent of all FXS cases are caused by aberrant
hypermethylation and hyperexpansion of a trinucleotide (CGG)
repeat in the 5′ untranslated region of the FMR1 gene (Pieretti
et al., 1991; Sutcliffe et al., 1992) located on chromosome Xq27.3
(Fu et al., 1991; Verkerk et al., 1991). The trinucleotide repeat
in most normal (NL) individuals ranges from 5 to 44 repeats,
although some individuals may carry intermediate or gray zone
(IM/GZ) alleles of 45 to 54 repeats. Individuals with expanded
alleles of 55 to 199 repeats are considered premutation (PM)
carriers, while the presence of 200 or more repeats, almost
always accompanied by methylation of the CpG dinucleotides,
is indicative of a full mutation (FM) (Kronquist et al., 2008).
Generally, clinical manifestation of FXS only occurs in carriers
of methylated FM alleles.
The PM allele is meiotically unstable, especially when it
lacks AGG triplet interruptions, resulting in increased risk of
expansion to a FM allele when transmitted from females to
offspring (Fernandez-Carvajal et al., 2009). This risk increases
with PM allele size, reaching 90% when the PM allele is > 90
repeats (Nolin et al., 2003, 2011) and > 98% if the PM allele
is > 100 repeats (Nolin et al., 2011). Some PM carriers may
also display mild developmental delay and behavioral issues
(Bailey, 2004). Moreover, a significant fraction of PM carriers
(40% males and 8–16% females) are affected by late-onset fragile
X-associated tremor / ataxia syndrome (FXTAS; OMIM 300623)
(Jacquemont et al., 2004; Rodriguez-Revenga et al., 2009).
Another late-onset condition, fragile X-associated premature
ovarian insufficiency (FXPOI; OMIM 311360) aﬄicts 20% of
female PM carriers (Rodriguez-Revenga et al., 2009; Hoyos and
Thakur, 2017).
Currently, molecular testing for FXS is only introduced to
individuals with a family history of FXS and associated diseases,
or individuals with clinical features suggesting FXS, FXTAS,
FXPOI or intellectual disability (ACOG, 2017). Lately, there
has been increased interest in early detection in conjunction
with intervention for FXS. Early detection of FXS before the
formative years could allow for more effective intervention and
minimization of a family’s diagnostic odyssey (Bailey, 2004).
Furthermore, recent studies have shown promise in the treatment
of FXS particularly in early childhood (Castagnola et al., 2017;
Ligsay et al., 2017). Early detection of PM carrier status allows
appropriate counseling on the risks of FXS transmission, and
effects of FXPOI or FXTAS, for better family planning and
psychological preparedness (Abrams et al., 2012; Tassone, 2014;
Hagerman et al., 2017). As the combined population prevalence
of FM and PM carriers is less than 1% (Hagerman et al., 2017),
there has been recent interest in developing cost-effective and
rapid screening strategies to identify PM and FM carriers.
Dried blood spots were previously shown to be suitable
DNA sources for large-scale FXS screening of boys with mental
retardation using a regular repeat-spanning PCR method (Tzeng
et al., 2001; Chow et al., 2003). Tassone et al. later demonstrated
that triplet-primed PCR (TP-PCR) and capillary electrophoresis
was a sensitive method for second-tier identification of FXS
from dried blood spot-derived DNA after a first-tier regular PCR
to identify and exclude the majority normal samples (Tassone
et al., 2008). However, like the earlier studies, the strategy
was not gender-neutral and the first-tier screen was unable to
exclude a large percentage of normal female samples, resulting
in a significant proportion of normal samples being subjected
to the second-tier assay. Subsequently, an improved screening
assay involving fluorescent TP-PCR followed by capillary
electrophoresis (CE) was reported and used for population
screening studies (Tassone et al., 2012).
We recently described a novel single-step screening strategy
for rapid identification of FMR1 CGG repeat expansions based on
melt curve analysis (MCA) of TP-PCR products (Teo et al., 2012;
Rajan-Babu et al., 2015). This strategy was validated on genotype-
known DNA isolated from peripheral blood leukocytes or from
cell cultures (Rajan-Babu et al., 2016). To assess the accuracy of
the TP-PCR MCA assay when performed on DNA isolated from
dried blood spots, we conducted a double-blinded study using
dried blood spots obtained from a high risk population, whose
genotypes had previously been determined using a different
screening method (Winarni et al., 2012). The gender-neutral
property of our proposed strategy enables its application to FXS
screening in both males and females.
MATERIALS AND METHODS
FXS Reference DNA and Blood Spot
Samples
Four genomic DNA samples (NA20232, NA20230, NA20234,
and NA20236) derived from lymphoblastoid cell lines obtained
from Coriell Cell Repository (CCR; Coriell Institute for Medical
Research, Camden, NJ, United States) were used as FMR1 IM/GZ
(46–54 repeats) boundary markers. One hundred and fifty-one
previously genotyped dried blood spot samples of individuals
with intellectual disability or autism spectrum disorder (75 male
and 76 female) were screened in a blinded fashion, with only
gender and blood spot identification number (ID) available to the
operator. This study was approved by the Institutional Review
Boards of the National University of Singapore (B-16-150E)
and the Diponegoro University Faculty of Medicine Semarang
(PUPT 2016 – Fragile X). The authors assert that all procedures
contributing to this work comply with the ethical standards of
the relevant national and institutional committees on human
experimentation and with the Declaration of Helsinki, as revised
in 2013.
DNA Extraction From Dried Blood Spots
One 6 mm disk was punched out from each dried blood sample
spotted onto an FTA card (QIAcard FTA; Qiagen, Valencia, CA,
United States). The QIAamp DNA Mini Kit or QIAamp DNA
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Micro Kit (Qiagen, Hilden, Germany) was used to extract DNA
from each disk according to manufacturer’s instructions. The
exception when using the QIAamp DNA Micro Kit was the
addition of 200 µL of ethanol to the lysate immediately prior
to its transfer into the QIAamp MinElute spin column, which
significantly improved DNA recovery yield. DNA extracted using
QIAamp DNA Mini Kit and QIAamp DNA Micro Kit were
eluted in the minimum volume of 50 ul and 20 ul, respectively,
according to the manufacturer’s recommendations. DNA samples
were quantified using the NanoDrop 1000 (ThermoScientific)
and stored at−20◦C until use.
Triplet-Primed PCR (TP-PCR) and Melt
Curve Analysis (MCA)
TP-PCR and MCA was performed according to Rajan-Babu et al.
(Rajan-Babu et al., 2015) except that final reaction volume was
25 µL and the Rotor-Gene Q High Resolution Melt instrument
(RGQ HRM; Qiagen) was used. Each reaction contained 2 µL
of dried blood spot-extracted DNA as template, while 50 ng of
genomic DNA was used for the CCR IM/GZ control samples.
For reactions that did not produce a melt peak, due to low DNA
concentration, TP-PCR MCA was repeated with 5 µL or 7.5 µL
of extracted DNA. Post-PCR amplicon melting was performed
using RGQ HRM, and involved an initial denaturation step at
95◦C for 1 min, a hold at 60◦C for 1 min, and gradual increase
in temperature from 65◦C to 95◦C in 0.5◦C increments with
a 5-s hold at each step. Melt peaks were generated by plotting
the negative first derivative of change in fluorescence vs. the
change in temperature (−dF/dT) against temperature within the
HRM module. The melt peak temperature (Tm) of the last peak
before falling to baseline, which corresponds to the temperature
exhibiting the greatest change or drop in fluorescence intensity
or highest −dF/dT value, was determined. Samples with Tm
significantly to the right of the upper IM/GZ Tm boundary
were classified as expansion-positive or expanded, while samples
significantly to the left of the lower IM/GZ Tm boundary were
classified as expansion-negative or non-expanded.
Fluorescent TP-PCR and Capillary
Electrophoresis (CE)
Fluorescent TP-PCR and CE were performed with conditions
identical to Rajan-Babu et al. (Rajan-Babu et al., 2015) except
that Taq Extender additive was omitted, and either GeneScanTM
500 ROXTM Size Standard (Applied Biosystems – Life
Technologies, Carlsbad, CA, United States) or MapMarker1000 R©
(BioVentures, Murfreesboro, TN, United States) was used for
internal sizing during CE. Each reaction contained 2 µL of
dried blood spot-extracted DNA as template, while 100 ng
of genomic DNA was used for the CCR IM/GZ control
samples.
Fluorescent Regular/Repeat-Spanning
PCR and CE
Conditions for fluorescent regular/repeat-spanning PCR and CE
were similar to those for fluorescent TP-PCR and CE except that
the tail and TP primers were replaced with primer 5′-F1 (Teo
et al., 2012), 0.5 mM of each dNTP and 0.4 µM of each primer
were used in the PCR reaction, and 2 µL of each PCR product
was analyzed by CE.
FIGURE 1 | FMR1 TP-PCR MCA profiles of 75 male and 76 female dried blood spot-extracted DNAs. Gray melt peaks demarcate IM/GZ boundary. Blue melt peaks
are classified as non-expanded, while red melt peaks are expanded. Male sample #146 generated a melt peak with unusually low Tm (purple), while male sample
#145 generated an unusually flat melt peak profile (green).
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TABLE 1 | Correlation of dried blood spot TP-PCR MCA screen with known genotypes (n = 151).
Sample ID Sex FXS status FMR1 Genotypea TP-PCR MCAb TP-PCR and CEc
001 M NL 29 Neg n.d.
002 M NL 31 Neg n.d.
003 M NL 30 Neg n.d.
004 M NL 37 Neg n.d.
005 M NL 35 Neg n.d.
006 M NL 39 Neg n.d.
007 M NL 30 Neg n.d.
008 F NL 30,30 Neg n.d.
009 F NL 30,30 Neg n.d.
010 F NL 30,30 Neg n.d.
011 F NL 30,30 Neg n.d.
012 M NL 22 Neg n.d.
013 M NL 31 Neg n.d.
014 M NL 31 Neg n.d.
015 M NL 31 Neg n.d.
016 M NL 29 Neg n.d.
017 F NL 28,30 Neg n.d.
018 F NL 31,31 Neg n.d.
019 M NL 31 Neg n.d.
021 F NL 31,31 Neg n.d.
022 M NL 35 Neg n.d.
023 F NL 30,39 Neg n.d.
024 F NL 29,32 Neg n.d.
025 F NL 31,31 Neg 30/35
026 M NL 31 Neg n.d.
027 M NL 31 Neg n.d.
028 F NL 29,29 Neg n.d.
029 M NL 36 Neg n.d.
030 M NL 29 Neg n.d.
031 M NL 30 Neg n.d.
032 M NL 38 Neg n.d.
033 F NL 30,30 Neg n.d.
034 M NL 30 Neg n.d.
035 M NL 30 Neg n.d.
037 M NL 32 Neg n.d.
038 M NL 30 Neg n.d.
039 F NL 29,29 Neg n.d.
040 F NL 30,30 Neg n.d.
041 F NL 30,30 Neg n.d.
042 M NL 37 Neg n.d.
043 F NL 31,32 Neg n.d.
044 M FM 545 Pos > 200
045 F NL 28,30 Neg n.d.
046 M NL 31 Neg n.d.
049 F NL 29,29 Neg n.d.
051 M NL 31 Neg n.d.
052 F NL 40,40 Neg 39/44
053 F NL 30,30 Neg n.d.
054 M NL 29,51 Neg n.d.
055 F NL 29,30 Neg n.d.
056 M NL 31 Neg n.d.
057 F NL 30,36 Neg n.d.
058 M NL 30 Neg n.d.
(Continued)
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TABLE 1 | Continued
Sample ID Sex FXS status FMR1 Genotypea TP-PCR MCAb TP-PCR and CEc
059 F NL 28,28 Neg n.d.
060 M NL 29 Neg n.d.
061 F NL 20,20 Neg n.d.
062 F NL 27,35 Neg n.d.
063 F NL 29,29 Neg n.d.
064 F NL 29,36 Neg n.d.
065 M NL 30 Neg n.d.
066 M NL 28 Neg n.d.
067 F NL 29,36 Neg n.d.
068 F NL 24,26 Neg n.d.
069 M NL 26 Neg n.d.
070 M NL 33 Neg n.d.
071 F NL 26,26 Neg n.d.
072 M NL 37 Neg n.d.
073 M NL 27 Neg n.d.
074 M NL 26 Neg n.d.
075 F NL 27,34 Neg n.d.
076 M NL 28 Neg n.d.
077 M NL 28 Neg n.d.
078 M NL 28 Neg n.d.
079 M NL 29 Neg n.d.
080 F NL 28,28 Neg n.d.
081 F NL 30,30 Neg n.d.
082 M NL 29 Neg n.d.
083 M NL 30 Neg n.d.
084 F NL 30,30 Neg n.d.
085 M NL 29 Neg n.d.
086 F NL 29,29 Neg n.d.
087 M NL 36 Neg 36
088 F NL 28,28 Neg n.d.
089 F NL 28,28 Neg n.d.
090 M NL 29 Neg n.d.
091 M NL 30 Neg n.d.
092 F NL 28,28 Neg n.d.
093 F NL 27,27 Neg n.d.
094 F NL 30,30 Neg n.d.
095 M NL 20 Neg n.d.
096 M NL 29 Neg n.d.
097 M NL 21 Neg n.d.
098 F NL 28,35 Neg n.d.
099 F NL 28,35 Neg n.d.
100 F NL 28,40 Neg 29/41
101 F NL 27,27 Neg n.d.
102 M NL 27 Neg n.d.
103 M NL 26 Neg 29
104 F NL 27,27 Neg 29
105 F NL 25,25 Neg n.d.
106 M NL 28 Neg n.d.
107 M NL 30 Neg 30
113 F NL 29,29 Neg 29/30
114 M PM 110 Pos ∼100,115,125
125 M NL 29 Neg n.d.
126 M NL 30 Neg n.d.
(Continued)
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TABLE 1 | Continued
Sample ID Sex FXS status FMR1 Genotypea TP-PCR MCAb TP-PCR and CEc
127 M NL 23 Neg n.d.
128 M NL 30 Neg 30
131 M NL 29 Neg 29
133 M NL 32 Neg 30
136 F NL 20,28 Neg n.d.
137 F NL 15,29 Neg n.d.
138 M NL 31 Neg 30
139 F NL 20,30 Neg n.d.
140 F NL 28,28 Neg 29/30
141 F NL 28,28 Neg n.d.
142 F NL 25,30 Neg n.d.
143 F NL 29,31 Neg n.d.
144 F NL 30,30 Neg n.d.
145 M NL 30 Neg 28
146 M NL 10 Neg 9
147 F NL 28,28 Neg 29/30
148 M NL 30 Neg n.d.
149 M PM 83 Pos ∼80
150 F NL 29,29 Neg n.d.
151 F NL 22,30 Neg n.d.
152 F PM 29,128 Pos 29/∼130, > 200
153 M NL 29 Neg 29
154 F FM 28,110,222,441,504,900 Pos 29/∼95, > 200
155 F NL 29,29 Neg n.d.
156 F NL 31,31 Neg n.d.
157 F FM 25,185,324,551,658,800 Pos 24/ > 200
158 M NL 30 Neg n.d.
159 F FM 32,423-850 Pos 32/ > 200
160 F FM 24,225 Pos 24/ > 200
161 F NL 31,31 Neg n.d.
162 F PM 29,76 Pos 30/∼75
163 M NL 36 Neg n.d.
164 M NL 29 Neg 29
165 F FM 28,288,532 Pos 29/ > 200
166 F FM 28,223,446,769 Pos 29/ > 200
167 M NL 29 Neg n.d.
168 M NL 29 Neg n.d.
169 F PM 29,125 Pos 29/∼130,175
170 F NL 30,30 Neg n.d.
171 F FM 34,290 Pos 34/ > 200
172 F PM 30,101 Pos 30/∼75,100,120
210 F NL 28,28 Neg n.d.
211 M NL 29 Neg 29
212 F PM 30,150 Pos 30/∼130,135,150,170,180
213 F NL 29,29 Neg n.d.
Total 75M, 76F 8FM (1M, 7F), 7PM (2M, 5F) 136 NL (72M, 64F) 15 Pos (3M, 12F) 136 Neg (72M, 64F)
Male (M) and female (F) samples subjected to sizing confirmation by fluorescent TP-PCR and capillary electrophoresis (CE) are underlined, of which the expansion-positive
samples are further indicated in bold. aCGG repeat genotypes of all screened samples have been determined previously (Winarni et al., 2012). bTP-PCR MCA screening
results are shown as Pos (expanded) or Neg (non-expanded). cFluorescent TP-PCR and CE results are shown as number of CGG repeats. Premutation (PM) allele sizes
are approximated to the nearest five repeats, and full mutations (FM) are indicated as > 200 repeats. NL, samples with normal allele(s) only; n.d., not determined.
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RESULTS
Dried Blood Spot DNA Concentrations
Each 6 mm diameter disk of dried blood spot yielded DNA
amount ranging from 20 to 1590 ng. Samples with DNA
input of at least 20 ng consistently produced clearly analyzable
TP-PCR MCA results, although DNA input as low as 3 ng
was able to produce melt peaks that were sufficient for
analysis.
TP-PCR MCA Classification of Dried
Blood Spot DNA Samples
DNA from dried blood spots of 151 individuals with intellectual
disability or autism spectrum disorder were screened for the
presence of an expanded FMR1 CGG repeat using the FMR1
TP-PCR MCA assay. Among both the male and female groups,
a majority of the samples displayed melt peaks (last peak) with
Tms that were lower than the IM/GZ Tm range, indicating that
these samples are non-expanded (Figure 1). Three male and 12
female samples generated TP-PCR MCA peaks with Tms that
were higher than the IM/GZ Tm range, and were classified as
expanded. There was a clear separation between the melt peaks
of the 15 expansion-positive samples and the melt peaks of the
other 136 expansion-negative samples.
Sizing Confirmation of All
Expansion-Positive and Selected
Expansion-Negative Samples
All 15 expansion-positive samples (three male and 12 female),
together with 19 representative expansion-negative samples (12
male and seven female) were subjected to sizing confirmation
by fluorescent TP-PCR and CE. Fluorescent TP-PCR CE analysis
of the three expansion-positive and 12 representative expansion-
negative male samples confirmed their expanded and non-
expanded classifications, respectively. Fluorescent TP-PCR CE
further determined that expanded males #114 and #149 each
carry a PM allele while expanded male #044 carries a FM allele
(Table 1 and Figure 2).
The classifications of all 12 expansion-positive and seven
representative expansion-negative female samples were also
confirmed after fluorescent TP-PCR CE analysis. Fluorescent
TP-PCR CE also determined that four expanded females were
PM carriers while eight expanded females were FM carriers
(Table 1). Representative TP-PCR MCA melt peak profiles and
CE electropherograms of expansion-negative and expansion-
positive female samples are shown in Figure 3.
To further corroborate the correlations, all 34 samples that
were analyzed by fluorescent TP-PCR CE were also subjected
to fluorescent regular PCR across the FMR1 CGG repeat and
CE. Fluorescent regular PCR CE results were generally correlated
with the TP-PCR MCA classification results, especially for the
NL and PM male samples and the PM and some NL female
samples. Unlike the TP-PCR MCA screen or fluorescent TP-
PCR CE sizing, however, fluorescent regular PCR CE failed to
unambiguously detect large expansions from FM male and female
samples (Figures 2, 3). Furthermore, compared to repeat sizing
by simple peak counting of fluorescent TP-PCR CE products,
the calculated repeat size after fluorescent regular PCR CE ([base
pair size – 209] ÷ 3) was consistently shorter by ∼4 repeats
(Figures 2, 3). This underestimation is likely due to the
anomalous mobility of GC-rich amplicons, thus requiring some
form of mobility correction, such as the use of standard curves,
in order to obtain accurate repeat sizing from fluorescent regular
PCR analysis (Biancalana et al., 2015).
Two of the 12 expansion-negative male samples that
underwent sizing confirmation were selected because they
generated unexpected TP-PCR MCA melt peak profiles. Sample
#145 exhibited an unusually flat melt peak profile while sample
#146 produced a distinct melt peak with unusually low Tm
of 83.42◦C (Figure 1). Fluorescent TP-PCR CE indicated
that the FMR1 allele in #146 contains only 8 repeats, which
adequately explains its exceptionally low Tm in TP-PCR MCA
(Figure 4, bottom). In contrast, fluorescent TP-PCR CE of #145
was unsuccessful, suggesting insufficient sample DNA for the
reaction, and consistent with the observed flat TP-PCR MCA
melt peak profile. However, fluorescent regular PCR CE produced
an amplicon peak with a calculated CGG repeat size of 24 before
mobility correction. An aliquot of the fluorescent regular PCR
product was then used as template for TP-PCR amplification,
and this time a fluorescent TP-PCR peak pattern was observed,
indicating that the FMR1 allele in #145 contains 28 uninterrupted
CGG repeats (Figure 4, top).
Reproducibility of Sample Classification
From Dried Blood Spot-Derived DNA
Two expansion-positive male and two expansion-positive female
dried blood spots were selected for re-extraction using a separate
punch from the same blood spot, and DNAs were eluted in 25 µL
and re-analyzed in 10 replicates to test the reproducibility of
the TP-PCR MCA assay. In the initial screen of 151 samples,
samples #044 and #169 produced good melt peak profiles, sample
#165 produced a slightly poorer melt peak profile, while sample
#114 displayed the flattest melt peak profile. For each sample,
the 10 replicates displayed melt peak temperatures consistent
with expanded status, although Tm variation across replicates
differed among samples, with samples #044 and #169 having
the lowest standard deviation (SD) of 0.11◦C, sample #165
having an intermediate SD of 0.17◦C, and sample #114 having
the highest SD of 0.53◦C (Figure 5). Sample #114 had the
lowest DNA concentration of ∼8 ng/µL, whereas the DNA
concentrations of the other three samples ranged from ∼26–
30 ng/µL. These results suggest that the TP-PCR MCA assay
generates reproducible results from dried blood spot-derived
DNA generally, although DNA template amount may play a role
in Tm accuracy.
Comparison With Sample Genotypes
Obtained From Previous Study
Screening results of all 151 samples were checked against
their previously determined genotypes (Winarni et al., 2012).
All 136 expansion-negative samples, and all 15 expansion-
positive samples, were correctly classified (Table 1). Since all
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FIGURE 2 | Concordance between TP-PCR MCA, fluorescent TP-PCR CE, and fluorescent regular PCR CE of two representative non-expanded male samples
(#107 and #087) and the three expanded male samples (#044, #114, and #149). Gray dotted lines indicate mean Tms of IM/GZ boundary. All three assays gave
concordant results, except that fluorescent regular PCR CE failed for FM sample #044.
FIGURE 3 | Concordance between TP-PCR MCA, fluorescent TP-PCR CE, and fluorescent regular PCR CE of two representative non-expanded female samples
(#052 and #104) and three representative expanded female samples (#162, #166, and #172). All three assays gave concordant results, except that fluorescent
regular PCR CE failed to detect the FM allele of sample #166.
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FIGURE 4 | Confirmation of expansion-negative status of samples with unusual results. Top (#145), failed fluorescent TP-PCR CE but successful fluorescent regular
PCR CE suggests low DNA concentration. Bottom (#146), fluorescent TP-PCR CE analysis reveals a short CGG repeat. Fluorescent TP-PCR from an aliquot of
fluorescent regular PCR product successfully generates a fluorescent TP-PCR CE profile, allowing accurate CGG repeat sizing.
FIGURE 5 | Reproducibility of the TP-PCR MCA classification from dried blood spot-derived DNA. Samples #044 and #169, and to a lesser extent sample #165,
generated reproducible and distinct melt peak profiles as compared to sample #114.
expansion-positive samples in the screen were followed up by
fluorescent TP-PCR CE sizing, their genotypes could also be
compared to their previously determined genotypes. All sample
genotypes were concordant except for a minor difference in one
sample which had been genotyped as a PM female, but fluorescent
TP-PCR CE detected evidence of mosaicism for PM and FM
alleles (#152) (Figure 6). This genotyping difference, however,
does not alter the fact that the TP-PCR MCA screen correctly
classified sample #152 as expanded, although further testing will
be required to confirm its exact expansion and disease status.
DISCUSSION
We recently developed a rapid and cost-effective alternative
for FXS screening, using a combinatory approach of TP-PCR
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FIGURE 6 | Premutation/full mutation mosaisicm in female sample #152. Fluorescent TP-PCR CE indicates the presence of a ∼130-repeat PM allele, and a FM
allele as evidenced by the presence of fluorescent peaks extending beyond 200-repeats.
and MCA (Teo et al., 2012; Rajan-Babu et al., 2015), and also
performed a technical validation of the TP-PCR MCA assay to
identify optimum performance parameters (Rajan-Babu et al.,
2016). We have now demonstrated that this assay is equally
accurate when applied to dried blood spot-derived DNA, which
is the most readily available and stable DNA source in the context
of large-scale or population-based screening, such as newborn
screening.
As this assay is optimized to detect expanded alleles regardless
of gender, separate analysis and interpretation by gender is
unnecessary, hence saving precious time in the screening
process. Additionally, confounding factors such as karyotype
abnormalities (such as XXX, XXY, and XXYY) will not adversely
affect the ability of this assay to detect an FMR1 expansion when
it is present (Biancalana et al., 2015).
Population-screening approaches employing a first-tier
regular PCR are inefficient as 43 out of 64 normal females
(∼67%) in our test cohort require second-tier CGG-repeat
sizing. This is because normal females are excluded only when
two normal alleles are detected, and homozygous normal females
cannot be distinguished from the much rarer (< 0.1%) affected
females carrying a non-amplifiable FM allele. In contrast, the TP-
PCR MCA first-tier screening assay identified all 15 expanded
male and female samples out of the 151 samples screened
(∼10% of total sample count), with no false-positive samples
reflexed to CGG-repeat sizing. We also demonstrated that the
results generated by this assay are highly reproducible even from
dried blood spot-derived DNA, with Tms of replicate samples
showing minimal deviation.
Additionally, TP-PCR MCA can correctly detect expansions
even when DNA concentrations are as low as 1.5 ng/µL.
Furthermore, despite the variability of the melt peak profiles
generated when the quality of the dried blood spot-derived
DNA was sub-optimal, correct expansion classification was not
adversely affected. Moreover, while sample #145 (1.0 ng/µL) did
not generate a good melt peak profile, the melt peak observed
was sufficient for classification as non-expanded after the volume
of DNA template was increased to 7.5 µL. Therefore, TP-PCR
MCA is very sensitive for screening of FXS, and should be
preferred over cytogenetics even in developing countries which
lack advanced molecular diagnostic facilities, since this method
uses relatively inexpensive equipment.
As a first-tier screen, TP-PCR MCA does not determine
CGG-repeat size. Instead, it can be observed that alleles of
increasing repeat size will generally have a correspondingly
increased Tm. i.e., Tm(normal) < Tm(premutation) < Tm(full
mutation). For the application of TP-PCR MCA in the
context of population screening, suitable internal controls
that demarcate the IM/GZ boundary are essential in each
experiment. To allow for a gender-neutral screen, inclusion
of all four genomic DNAs (NA20230, NA20232, NA20234,
and NA20236) is advisable. Rapid identification of samples
suspected to carry expanded alleles would be achieved simply
though observation of melt peak Tm position relative to the
internal controls. All screen positive samples, as well as any
indeterminate/ambiguous samples, should be subjected to CGG-
repeat sizing for confirmation/verification of expansion status.
Since the TP-PCR MCA screen will also detect PM carriers,
who are not FXS-affected but are at risk of developing FMR1-
related late-onset conditions, genetic counseling should be
made available for families of carriers or affected individuals
who are identified from the screen. A TP-PCR MCA based
screening approach will be very useful for newborn screening
purposes as it enables identification of FMR1 CGG repeat
expansion in a single step from both males and females (Tassone,
2014). Early identification will also be extremely beneficial
for targeted treatment that has to be executed early in life
(Ligsay et al., 2017).
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